Now I have all the information I need. Let me produce the final review.

## Summary

This paper evaluates small language models (≤3B parameters) and small vision-language models against large, medically domain-adapted LMs/VLMs on clinical text summarization (MeQSum) and radiology report generation (MIMIC-CXR). The key findings are that (a) after LoRA fine-tuning, small LMs can match or exceed large medical LMs on text metrics, (b) a "safety collapse" occurs below ~1B parameters where hallucination rates spike, and (c) for VLMs, small models lag behind large ones even after fine-tuning — a modality-specific asymmetry.

## Strengths

1. **Safety collapse threshold (Table 3)**: The paper provides granular evidence that hallucination rates remain stable at ~2–3% down to 1.7B parameters but spike to 18.3% (360M) and 75% (270M) below that. This empirically grounds a minimum viable scale (~1B) for clinical text deployment — a finding that goes beyond prior work comparing only a few model sizes.

2. **Modality-specific contrastive finding**: Small VLMs lag behind large VLMs on radiology report generation even after extensive fine-tuning (10K pairs), while small LMs can be competitive on text summarization after LoRA. This modality asymmetry — that language tasks compress well but visual reasoning demands capacity — is a non-obvious finding demonstrated within a unified evaluation framework (Table 4 vs. Figure 3).

3. **Multi-prompt averaging**: Using 5 distinct prompt templates and averaging results (Table 2) treats prompt selection as an experimental variable rather than cherry-picking a single favorable template, strengthening the zero-shot comparison.

4. **Concrete hardware differential reporting**: The paper notes that small models required L4 GPUs versus L40S for large baselines (line 112), grounding efficiency claims in verifiable deployment conditions.

## Weaknesses

### Major

1. **Asymmetric fine-tuning comparison undermines the headline claim.** The paper's central claim — that LoRA-fine-tuned small LMs "outperform large LMs across all metrics" (line 231) — rests on comparing fine-tuned small models against large models evaluated *only* with ICL (zero/few-shot). Large LMs (BioMistral 7B, Med-LLaMA 8B, OpenBioLLM 8B) have a dash ("-") for LoRA in Figure 3, and line 120 explicitly states LoRA was applied "to each small LLM" only. Every claim that a small LM outperforms a large LM is therefore: *small LM adapted to the evaluation data* outperforms *large LM not adapted to that data*. While the large models benefit from domain-adaptive pre-training, the comparison conflates task adaptation with model scale. A cleaner test would fine-tune both sides with the same protocol. This does not invalidate the paper but substantially weakens its most prominent result.

2. **Collapse analysis methodology is opaque (Table 3).** The paper introduces Task Adherence, Hallucination Rate, Concept Recall, Prompt Robustness, and a composite Readiness Score — potentially the most novel contribution — but provides no methodology for how any were computed. Were these judged by human raters (with inter-rater agreement?), derived from automated heuristics, or extracted from NLP metrics? Hallucination Rate cites Li et al. (2024a) once, but the others have no grounding. Without this information, Table 3 is a set of unverifiable numbers and the central "collapse" finding cannot be reproduced or critically assessed.

### Minor

3. **No uncertainty or significance measures.** All results are single-point estimates across 250 test samples. No confidence intervals, standard deviations, or significance tests are reported. Some comparisons are close (e.g., SmolLM2-1.7B ICL BERTScore 90% vs OpenBioLLM-8B 90%) and could flip with a different split. This weakens the evidential strength of comparative claims.

4. **LoRA training hyperparameters undisclosed.** No rank, alpha, target modules, learning rate, number of epochs, or training set size are reported for the LoRA/QLoRA fine-tuning experiments. This prevents reproduction.

5. **Two-shot results not tabulated.** The text (line 112) reports two-shot gains (~2–3% for some models) but no table is provided, making these claims impossible to verify against reported metrics.

6. **VLM comparison conditions unclear.** It is not stated whether the large VLMs (Med-Flamingo, LLaVA-Med) were also fine-tuned on the 10K MIMIC-CXR pairs or evaluated zero-shot. If the latter, this introduces a similar asymmetry issue in the opposite direction.

7. **Training/validation split not described.** The paper mentions a "held-out test set of 250 samples" (line 82) but does not specify how many samples were used for LoRA training versus held out for validation.

### Trivial

8. **"SmolLM3-3B" in Table 3** (line 126) is inconsistent with "SmolLM2" used everywhere else in the paper — likely a typo.

## Nice-to-Haves

- Including the two-shot results in a table would make the few-shot analysis more concrete.
- Training/validation split details and LoRA hyperparameters would strengthen reproducibility.
- Explicitly stating the fine-tuning status of large VLMs in the MIMIC-CXR experiments would remove ambiguity.
- Fine-tuning the large medical LMs on the same data with the same LoRA protocol would make the central comparison fair and definitive.

## Removed Points

- **Criticism about decoding hyperparameters being unjustified (k=3, p=0.9, T=0.3):** The paper states these "strike a balance between fidelity and variability" (line 78). Applying the same decoding strategy across all models is standard isolation practice. Removed as a nitpick.
- **Strength about "LoRA-fine-tuned small LMs surpassing large LMs across all metrics":** This strength conflicts with verified weakness #1 (asymmetric comparison). Keeping it would be misleading; it is removed. The zero-shot competitiveness (Table 2) remains a cleaner, defended strength.
- **Criticism about "missing related works":** Not included per rules (cannot verify external references).
- **"Reproducibility concerns about undisclosed hyperparameters":** Kept as Minor (genuinely missing) but softened from the critic's stronger framing — these are addressable in a revision, not fatal.

## Novel Insights

None beyond the paper's own contributions.

## Suggestions

1. **Highest leverage**: Fine-tune the large medical LMs (BioMistral 7B, Med-LLaMA 8B, OpenBioLLM 8B) on the same MeQSum data with the same LoRA protocol and compare all models under symmetric conditions. If small models still match/exceed large ones, the claim becomes much stronger. If large models pull ahead (as in the VLM case), the corrected finding is still valuable.
2. Provide a clear methodology subsection for the collapse analysis: define each dimension operationally, describe any human annotation protocol with inter-rater reliability, and specify how the composite Readiness Score is aggregated.
3. Report confidence intervals or standard deviations for all metrics.
4. Specify whether large VLMs were fine-tuned on MIMIC-CXR or evaluated zero-shot.

## Score and Decision

**Calibration Anchors (all retrieved rounds):**

| Anchor | Avg Score | Round | Comparison |
|--------|-----------|-------|------------|
| "Revisiting the Scaling Effects of LLMs on Medical Reasoning" | 4.00 | R1,R2 | Similar evaluation study of model scaling, but with overclaimed clinical relevance. Our paper has broader scope (two modalities, multiple adaptation methods) but similar methodological issues. Slightly stronger. |
| "Enhancing Small Medical Learners with Privacy-preserving Contextual Prompting" | 6.00 | R1,R2 | Cleaner experimental design and clearer contributions. Our paper's central comparison is flawed by asymmetry; thus weaker. |
| "ClinicalBench: Can LLMs Beat Traditional ML Models in Clinical Prediction?" | 5.50 | R1,R2 | Mixed reviews; findings considered somewhat predictable. Our paper has more interesting/nuanced findings but a more problematic central claim. Comparable. |
| "Do Current Large Language Models Master Adequate Clinical Knowledge?" | 4.33 | R2 | Evaluation study with opaque methodology and overclaimed conclusions. Our paper has similar issues but is broader in scope. Comparable or slightly stronger. |
| "Context Clues: Evaluating Long Context Models for Clinical Prediction" | 7.00 | R2 | Well-executed evaluation with released resources and thorough analysis. Our paper is clearly weaker. |
| "Multiple Choice Questions and LLMs: A Case Study with Fictional Medical Data" | 4.00 | R2 | Evaluation study with limited scope. Our paper is stronger in breadth and ecological validity. |
| "Large Language Models for Biomedical Knowledge Graph Construction" | 3.00 | R1 | Weak paper with major execution issues. Our paper is substantially stronger. |

**Round 1 bracket**: between 3.5 and 5.5.

**Round 2 narrowing**: Anchors at 4.33, 4.00, 5.50, 6.00, 7.00. Our paper sits between the 4.3–4.0 papers (comparable evaluation studies) and the 5.5–6.0 papers (cleaner contributions). Given the asymmetric comparison issue (which is structural, not cosmetic) and the opaque collapse analysis, the paper is closest to but slightly above the 4.0–4.33 cluster.

**Final score**: 4.5 — the paper tackles an important question with a broad evaluation framework, but the headline claim is undermined by an asymmetric comparison, and a claimed contribution (collapse analysis) lacks the methodological transparency needed for evaluation. These are fixable, but as-is the evidence does not support the paper's strongest conclusions.

MY FINAL SCORE: <score>4.5</score>
MY FINAL DECISION: <decision>Reject</decision>